Medispas 10 Tablets

babies: not applicable. lactating mother: consult your doctor before using this medication during breastfeeding.
pregnancy: drotaverine hcl and mefenamic acid tablets are unsafe to use during breastfeeding. human and animal studies suggest that this drug may cause harmful effects on developing babies.
consult your doctor. alcohol: it is unsafe to consume with drotaverine hydrochloride, mefenamic acid tablets.
driving: drotaverine hcl and mefenamic acid tablets may cause dizziness or sleepiness, and it could affect your ability to drive. do not drive if these symptoms occur.
kidney: drotaverine hcl and mefenamic acid tablets should be used with caution in patients with kidney disease. dose adjustment is required.
consult your doctor. liver: drotaverine hcl and mefenamic acid tablets should be used with caution in patients with liver disease.
dose adjustment is required. consult your doctor..

Nausea Vomiting Diarrhea Stomach pain Loss of appetite Dryness in mouth Feeling thirsty Heartburn.

MEDISPAS is an anti-spasmodic medicine. it works by relieving contractions in the smooth muscles of the abdomen.
it is a non-steroidal anti-inflammatory drug. it works by blocking chemical messengers which cause abdominal pain and inflammation..

If you miss a dose, take MEDISPAS as soon as possible. If it is near the time of the next dose, then skip the missed dose.
Take the prescribed dose on your regular time daily. Don't double the dose to catch up with the missed dose..

• MEDISPAS tablets are used to relieve abdominal pain • it is better to be taken with food to prevent stomach discomforts • do not drive after taking this medication because it can cause dizziness or sleepiness • do not drink alcohol while taking this medication because it can cause excessive drowsiness • consult your doctor if you have experienced diarrhoea and stop taking medication • your doctor may advise regular monitoring of liver and kidney function while taking this medication.

• drotaverine hcl + riociguat: concurrent use may result in increased hypotensive activities of riociguat. • drotaverine hcl + isosorbide mononitrate: concurrent use may result in increased vasodilatory activities. • mefenamic acid + ketorolac: concurrent use may result in enhanced gastrointestinal adverse effects. • mefenamic acid + aceclofenac: concurrent use may result in an increased risk of bleeding. • mefenamic acid + amiloride: concurrent use may result in reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity. • mefenamic acid + aspirin: concurrent use may result in an increased risk of bleeding and increased risk of cardiovascular events. • mefenamic acid + chlorthalidone: concurrent use may result in reduced diuretic effectiveness and possible nephrotoxicity. • mefenamic acid + cyclosporine: concurrent use may result in an increased risk of cyclosporine nephrotoxicity..